SCHEMBL5354380

SCHEMBL5354380

CCc1cc(CC)nc(SC)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.40
NOS2 P35228 1/20 0.40
KMT2A Q03164 3/20 0.35
THRB P10828 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
HTT P42858 2/20 0.35
PKM P14618 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
POLB P06746 1/20 0.34
HSP90AB1 P08238 1/20 0.33
ADORA3 P0DMS8 2/20 0.33
ADORA2A P29274 2/20 0.33
ESR1 P03372 1/20 0.32
TERT O14746 1/20 0.32
LMNA P02545 1/20 0.32
MEN1 O00255 2/20 0.32
HSP90AA1 P07900 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13064527 0.87 KMT2A (0.46) NOS3NOS2KMT2ATHRBHTT
SCHEMBL2462899 0.85 HTT (0.47) NOS3NOS2KMT2ATHRBKDM5B
SCHEMBL14872325 0.85 NOS2 (0.52) NOS3NOS2KMT2APOLBHSP90AB1
SCHEMBL13064252 0.82 KMT2A (0.39) KMT2ATHRBHTTALDH1A1GAA
SCHEMBL1178768 0.79 HCAR2 (0.39) KMT2AHTTADORA3ADORA2ALMNA
SCHEMBL12570442 0.78 MAPT (0.49) KMT2ATHRBHTTALDH1A1HSP90AB1
SCHEMBL11130289 0.76 KCNH2 (0.47) NOS2ESR1
SCHEMBL1179686 0.74 CYP1A2 (0.46) KMT2AALDH1A1GAAPOLBLMNA
SCHEMBL21280637 0.73 NOS3 (0.35) NOS3NOS2KDM5B
SCHEMBL12636463 0.73 PARP1 (0.47) NOS3NOS2KMT2AHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101514190-B Method for preparing heterocyclic compounds of methyl mercapto under ionic liquid catalysis UNIV DONGHUA 2011-06-08 CN claimed
CN-101514190-A Method for preparing heterocyclic compounds of methyl mercapto under ionic liquid catalysis UNIV DONGHUA (CN) 2009-08-26 CN claimed
CN-101391984-A Method for carrying out methylation to pyrimidine heterocyclic compound containing sulfhydryl by dimethyl carbonate UNIV DONGHUA (CN) 2009-03-25 CN claimed
CN-101514190-B Method for preparing heterocyclic compounds of methyl mercapto under ionic liquid catalysis UNIV DONGHUA 2011-06-08 CN disclosed
CN-101391984-B Method for carrying out methylation to pyrimidine heterocyclic compound containing sulfhydryl by dimethyl carbonate UNIV DONGHUA 2010-12-08 CN disclosed
CN-101514190-A Method for preparing heterocyclic compounds of methyl mercapto under ionic liquid catalysis UNIV DONGHUA (CN) 2009-08-26 CN disclosed
CN-101391984-A Method for carrying out methylation to pyrimidine heterocyclic compound containing sulfhydryl by dimethyl carbonate UNIV DONGHUA (CN) 2009-03-25 CN disclosed
US-7238685-B2 Benzo-fused heterocycles as endothelin antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2007-07-03 US disclosed
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits ACTELION PHARMACEUTICALS LTD. 2005-06-09 US disclosed
WO-2003013545-A1 NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS ACTELION PHARMACEUTICALS LTD (CH) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits EDNRA, EDNRB, ECE1 NOS3 493/4885NOS2 440/4885KMT2A 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.